These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10466753)

  • 1. Exploiting the p53 pathway for cancer diagnosis and therapy.
    Lane DP
    Br J Cancer; 1999 Jul; 80 Suppl 1():1-5. PubMed ID: 10466753
    [No Abstract]   [Full Text] [Related]  

  • 2. The regulation of p53-mediated transcription and the roles of hTAFII31 and mdm-2.
    Lu H; Lin J; Chen J; Levine AJ
    Harvey Lect; 1994-1995; 90():81-93. PubMed ID: 8803320
    [No Abstract]   [Full Text] [Related]  

  • 3. P53 and prognosis: new insights and further complexity.
    Vousden KH; Prives C
    Cell; 2005 Jan; 120(1):7-10. PubMed ID: 15652475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achilles' heel of cancer?
    Vogelstein B; Kinzler KW
    Nature; 2001 Aug; 412(6850):865-6. PubMed ID: 11528457
    [No Abstract]   [Full Text] [Related]  

  • 5. Turning the key on p53.
    Lane DP; Fischer PM
    Nature; 2004 Feb; 427(6977):789-90. PubMed ID: 14985740
    [No Abstract]   [Full Text] [Related]  

  • 6. Mdm2: keeping p53 under control.
    Piette J; Neel H; Maréchal V
    Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of p53 function.
    Woods DB; Vousden KH
    Exp Cell Res; 2001 Mar; 264(1):56-66. PubMed ID: 11237523
    [No Abstract]   [Full Text] [Related]  

  • 8. Mdm-2: "big brother" of p53.
    Momand J; Zambetti GP
    J Cell Biochem; 1997 Mar; 64(3):343-52. PubMed ID: 9057092
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategies for manipulating the p53 pathway in the treatment of human cancer.
    Hupp TR; Lane DP; Ball KL
    Biochem J; 2000 Nov; 352 Pt 1(Pt 1):1-17. PubMed ID: 11062053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.
    Wasylishen AR; Lozano G
    Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deconstruction of p53 functions and regulation.
    Haupt Y; Robles AI; Prives C; Rotter V
    Oncogene; 2002 Nov; 21(54):8223-31. PubMed ID: 12447685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 and mdm-2: interactions between tumor suppressor gene and oncogene products.
    Perry ME; Levine AJ
    Mt Sinai J Med; 1994 Sep; 61(4):291-9. PubMed ID: 7969222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for screening tumors for p53 status and therapeutic exploitation.
    Tullo A; D'Erchia AM; Sbisà E
    Expert Rev Mol Diagn; 2003 May; 3(3):289-301. PubMed ID: 12779005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture.
    Freedman DA; Levine AJ
    Cancer Res; 1999 Jan; 59(1):1-7. PubMed ID: 9892174
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDMX: a novel p53-binding protein with some functional properties of MDM2.
    Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
    EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties.
    Conseiller E; Debussche L; Landais D; Venot C; Maratrat M; Sierra V; Tocque B; Bracco L
    J Clin Invest; 1998 Jan; 101(1):120-7. PubMed ID: 9421473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?
    Fischer PM; Lane DP
    Trends Pharmacol Sci; 2004 Jul; 25(7):343-6. PubMed ID: 15219971
    [No Abstract]   [Full Text] [Related]  

  • 20. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
    Jones SN; Roe AE; Donehower LA; Bradley A
    Nature; 1995 Nov; 378(6553):206-8. PubMed ID: 7477327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.